Is lacosamide (Vimpat) more effective than levetiracetam (Keppra) for terminating seizures?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

No, Vimpat (lacosamide) is NOT more effective than Keppra (levetiracetam) for terminating seizures

Based on the highest quality evidence from the 2024 ACEP guidelines and the landmark ESETT trial, levetiracetam, fosphenytoin, and valproate demonstrate equivalent efficacy as second-line agents for status epilepticus, with approximately 45-47% of patients achieving seizure cessation. 1 Lacosamide was not included in these definitive trials and lacks the same level of evidence for acute seizure termination.

Evidence Quality and Hierarchy

The 2024 ACEP Clinical Policy provides Level A recommendations (the highest grade) stating that emergency physicians should treat benzodiazepine-refractory seizures with fosphenytoin, levetiracetam, or valproate with similar efficacy. 1 This recommendation is based on the ESETT trial, a Class I randomized controlled trial that demonstrated:

  • Levetiracetam: 47% seizure cessation at 60 minutes
  • Fosphenytoin: 45% seizure cessation at 60 minutes
  • Valproate: 46% seizure cessation at 60 minutes

These differences were not statistically significant. 1

Critically, lacosamide was not included in ESETT or any other Class I trials for status epilepticus. The 2024 guidelines and systematic reviews of status epilepticus management 2 mention lacosamide only as a potential add-on agent, not as an established second-line treatment for acute seizure termination.

Safety Profile Comparison

Levetiracetam demonstrated a superior safety profile in the ESETT trial:

  • Life-threatening hypotension: 0.7% (levetiracetam) vs 3.2% (fosphenytoin) vs 1.6% (valproate)
  • Cardiac arrhythmias: 0.7% (levetiracetam only)
  • Intubation rates: 20% (levetiracetam) vs 26.4% (fosphenytoin) vs 16.8% (valproate) 1

While these differences were not statistically significant, levetiracetam's trend toward fewer cardiovascular complications makes it particularly attractive in emergency settings.

Lacosamide's Evidence Base

The available evidence for lacosamide in acute seizure management is substantially weaker:

For Status Epilepticus:

  • A 2025 retrospective cohort study 3 found lacosamide statistically equivalent to levetiracetam and valproate as second-line therapy, but this is Class III evidence (retrospective, non-randomized)
  • A 2026 Japanese database study 4 showed similar in-hospital mortality between lacosamide and levetiracetam, but slightly better neurological outcomes with lacosamide—again, observational data only

For Chronic Epilepsy Management:

  • Lacosamide is FDA-approved only as adjunctive therapy for partial-onset seizures 5
  • Studies comparing lacosamide to levetiracetam for chronic epilepsy management 6, 7, 8 show equipotency, but these address maintenance therapy, not acute seizure termination
  • A 2022 Cochrane network meta-analysis 9 found lamotrigine and levetiracetam superior to most other agents for focal seizures, with no mention of lacosamide in acute settings

Clinical Algorithm for Second-Line Status Epilepticus Treatment

After adequate benzodiazepine dosing fails:

  1. First choice: Levetiracetam 60 mg/kg IV (max 4500 mg) over 10 minutes

    • Rationale: Equivalent efficacy to alternatives with best safety profile
    • Preferred in patients with cardiac disease, elderly, or hemodynamically unstable

  2. Alternative: Fosphenytoin 20 PE/kg IV at 150 PE/min

    • Rationale: Equivalent efficacy but higher cardiovascular risk
    • Avoid in patients with cardiac conduction abnormalities

  3. Alternative: Valproate 40 mg/kg IV at 10 mg/kg/min

    • Rationale: Equivalent efficacy
    • Contraindicated in women of childbearing potential

  4. Lacosamide is NOT recommended as a second-line agent based on current evidence

    • May be considered as third-line or add-on therapy if above agents fail
    • Typical dosing: 200-400 mg IV over 15 minutes 10, 2

Common Pitfalls

  • Do not delay treatment waiting for "the best drug"—all three guideline-recommended agents work equally well; choose based on patient factors and availability
  • Do not use lacosamide as first-line second-line therapy—it lacks Class I evidence for this indication
  • Do not assume newer equals better—levetiracetam (approved 1999) has far more robust evidence than lacosamide (approved 2008) for status epilepticus
  • Do not confuse chronic epilepsy management with acute seizure termination—lacosamide's role in maintenance therapy does not translate to acute settings

Nuances in Special Populations

The 2021 EANO-ESMO guidelines 10 note that for brain tumor-related epilepsy, levetiracetam and lamotrigine are preferred first-line agents due to lack of enzyme induction and favorable tolerability. Lacosamide is mentioned only as potential add-on therapy. This reinforces levetiracetam's broader applicability across clinical contexts.

For elderly patients, retrospective data 8 suggest lacosamide may be effective for chronic management, but this does not address acute seizure termination where levetiracetam remains the evidence-based choice.

References

Related Questions

Is lacosamide (Vimpat) as effective as levetiracetam (Keppra) for focal onset seizures?
How to switch a patient from Keppra (levetiracetam) to Vimpat (lacosamide)?
Can lacosamide and levetiracetam be co‑administered as adjunctive therapy for partial‑onset seizures in adults?
Is lacosamide 50 mg once daily plus levetiracetam 250 mg twice daily an adequate regimen for a 73‑year‑old woman with well‑controlled seizures?
When is lacosamide (Vimpat) favored over levetiracetam (Keppra)?
Is it safe to add spironolactone to my gout treatment with allopurinol and hypertension therapy with chlorthalidone, and what monitoring is required?
Is the blotchy rash on the arms and face that developed after starting lisinopril indicative of an allergic reaction?
What is the best medication to treat chronic occipital headaches?
What is the appropriate management for a 1.6 cm renal pole calculus?
Why does right-sided colon cancer present with anemia?
What is the recommended dose of fenofibrate when used concomitantly with atorvastatin, and how should dosing be adjusted based on renal function and atorvastatin dose?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.